 1. Patients newly diagnosed with AML or high-risk MDS undergoing induction chemotherapy or refractory or relapsed patients with AML or high-risk MDS who will receive first or second salvage chemotherapy. Salvage patients are defined as patients that achieved remission and relapsed or patients who were refractory to initial frontline chemotherapy 